NCT05839392 Novel Approaches to Target MECOM/EVI1 in AML
| NCT ID | NCT05839392 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Condition | AML, Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2023-12-13 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2023-12-13 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Eligibility Criteria
Inclusion Criteria: * AML with MECOM or atypical 3q26 rearrangements. * Age ≥18. * Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: * None
Contact & Investigator
Giovanni Roti
PRINCIPAL INVESTIGATOR
Department of Medicine and Surgery, University of Parma, Parma
Frequently Asked Questions
Who can join the NCT05839392 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying AML, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05839392 currently recruiting?
Yes, NCT05839392 is actively recruiting participants. Contact the research team at p.fazi@gimema.it for enrollment information.
Where is the NCT05839392 trial being conducted?
This trial is being conducted at Piacenza, Italy.
Who is sponsoring the NCT05839392 clinical trial?
NCT05839392 is sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. The principal investigator is Giovanni Roti at Department of Medicine and Surgery, University of Parma, Parma. The trial plans to enroll 24 participants.